Last reviewed · How we verify
NCT03339232
BCAA Supplemental Study
NA trial testing BCAA Supplement in Cirrhosis in 26 participants. Completed in 17 June 2019.
17 June 2019
Quick facts
| Lead sponsor | Loyola University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 26 |
| Start date | 2 October 2017 |
| Primary completion | 17 June 2019 |
| Estimated completion | 17 June 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- BCAA Supplement
- Physical Activity
Conditions studied
- Cirrhosis — all drugs for Cirrhosis →
Sponsor
Loyola University
Who can join
18 and older, any sex, with Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The central hypothesis of this study is that BCAA supplementation and BCAA supplementation plus low-intensity activity will improve muscle mass and HRQOL in cirrhotic patients compared to usual care
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Addressing the heterogeneity in liver diseases using biological networks.
Lam S, Doran S, Yuksel HH, Altay O, et al · · 2021 · cited 5× · PMID 32201876 · DOI 10.1093/bib/bbaa002
Verify or expand the search:
- PubMed search for NCT03339232
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BCAA Supplement
Trials testing the same drug.
- NCT05754125 — In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise · NA · unknown
Other recruiting trials for Cirrhosis
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
Other Loyola University trials
Trials by the same sponsor.
- NCT07517224 — Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer · NA · not yet recruiting
- NCT06486714 — Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty · NA · not yet recruiting
- NCT07216664 — Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants · NA · recruiting
- NCT07226505 — Effects of Core Strengthening Exercises for Treating TMD · NA · not yet recruiting
- NCT06525701 — Surgeon Core-strengthening Program as a Modifier for Exertion Associated With Vaginal Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03339232 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loyola University
- Last refreshed: 24 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03339232.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing